IOVA SHAREHOLDERS: Iovance Biotherapeutics, Inc. Investors are Reminded of the Pending Securities Fraud Class Action – Contact BFA Law by July 14 Deadline (NASDAQ:IOVA)

Core Viewpoint - A lawsuit has been filed against Iovance Biotherapeutics, Inc. and certain senior executives for potential violations of federal securities laws, particularly related to the company's performance and treatment timelines for its melanoma drug Amtagvi [1][2]. Company Overview - Iovance Biotherapeutics is a commercial-stage biopharmaceutical company focused on developing treatments for melanoma and other solid tumor cancers [3]. - The company launched its key melanoma treatment, Amtagvi, in February 2024, administered at authorized treatment centers (ATCs) [3]. Allegations and Issues - The lawsuit alleges that Iovance misrepresented the effectiveness of its ATCs in driving demand for Amtagvi, while in reality, the ATCs faced long timelines for patient treatment and high patient drop-off rates due to ineffective patient identification and selection [4]. - The company reported disappointing financial results for Q1 2025, revising its full-year 2025 revenue guidance downward, citing slow treatment timelines and high patient drop-off as contributing factors [5]. Stock Performance - Following the announcement of poor financial results, Iovance's stock price fell over 44%, dropping from $3.17 per share on May 8, 2025, to $1.75 per share on May 9, 2025 [6].